Illumina, Inc. (ILMN) Earnings Call Transcript & Summary
February 10, 2022
Earnings Call Speaker Segments
Salli Schwartz
executiveGood afternoon, everyone, and thanks for joining the call covering our fourth quarter and full year 2021 results. On today's call, we'll go over the financial results that were issued after the market closed and share some commentary about our commercial activity, and after that we'll open things up for a question-and-answer session. If you haven't yet looked at the earnings release, you can find it in the Investor Relations section of our website at illumina.com. With us from Illumina today are Francis deSouza, President and Chief Executive Officer, and Sam Samad, Chief Financial Officer. Francis will give an update on how Illumina's business is doing, and Sam will walk through our financial results, which include GRAIL. As a reminder, while the European Commission's investigation into Illumina's acquisition of GRAIL is pending, the commission has adopted an order that requires Illumina and GRAIL to be held and operated as distinct and separate entities for an interim period. A monitoring trustee oversees compliance with that order. During this period, Illumina and GRAIL may not share confidential business information unless legally required, and GRAIL has to be run independently and exclusively in GRAIL's best interest. Any commercial interactions between the two companies must be conducted at arm's length. This call is being recorded, and the audio portion will be archived in the Investors section of our website. We intend for all forward-looking statements about our financial results and commercial activity made on today's call to be protected under the Private Securities Litigation Reform Act of 1995. Forward-looking statements carry risks and uncertainties. Actual events or results could differ materially from those projected or discussed. All forward-looking statements rest on information currently available, and Illumina undertakes no obligation to update these statements. To better understand the risks and uncertainties that could cause actual results to differ, we point you to the documents Illumina files with the Securities and Exchange Commission, including Illumina's most recent Forms 10-Q and 10-K; with that, I'll now hand the call over to Francis.
Francis deSouza
executiveThanks, Salli. Good afternoon, everyone. I'm glad to be here to talk about how sticking with innovation is fueling our growth and helping us tap the potential of the genome. I'll focus my remarks on a handful of key topics, beginning with the strong close to the year and the outstanding results we delivered for 2021, and then I'll explain how our platforms and the markets we serve produced those results. After that, I'll wrap up by calling out a few of the many trends that should underpin our momentum and keep us growing in 2022 and beyond. Let's begin with the numbers for the fourth quarter and for the full year 2021. Revenue in the fourth quarter came in at about $1.2 billion, up 26% from a year earlier, with robust growth in both instruments and consumables and in every region. For all of 2021, revenue exceeded $4.5 billion, a rise of 40% compared with the prior year, which reflects 76% growth in sequencing instruments and 43% growth in sequencing consumables. Demand for our instruments is at record levels across the throughput range and around the world. During 2021, we shipped over 3,200 sequencing instruments and brought on more than 930 customers that are new to our instruments, which is over 50% higher than either 2020 or 2019. Now let me go through each platform, beginning with high throughput. In 2021, we shipped 384 NovaSeq units, with over one-third of those going toward oncology testing. About half of NovaSeq orders that year involved customers who were either unfamiliar with high throughput or had never purchased from Illumina before. Consumable pull-through per NovaSeq instrument in 2021 came in above $1.3 million — the highest average we have recorded — despite placements being more than twice what they were the previous year. Moving to mid-throughput: we shipped more than 1,100 NextSeq systems during 2021, exceeding 1,000 for the first time and almost doubling our 2020 shipments. That volume came from rising demand for NextSeq 550 in clinical uses such as oncology testing and reproductive health, along with demand for NextSeq 1000 and 2000 as customers move into multi-omic applications. Over 20% of NextSeq 1000 and 2000 units this year went to customers new to Illumina, as we keep seeing new customers adopt higher throughput applications; on low throughput, we shipped over 1,600 units in 2021, another record, helped in part by adding more than 700 new customers. If we look at our continued strong growth through the lens of our markets, our clinical markets today include testing for oncology, reproductive health and genetic disease. In 2021, shipments of consumables to clinical markets increased by forty-two percent. Oncology testing was a major driver of that growth, as numerous customers expand comprehensive genomic profiling, known as CGP, and shift toward liquid biopsy and monitoring. Worldwide demand for our oncology offerings continues to present expanding opportunities—among them, new studies launching in Europe and Asia that use our research-use only TruSight Oncology 500 assay. As one example, our recently announced joint research effort with the National Cancer Center Japan will focus on personalized cancer treatments for patients with nasopharyngeal carcinoma, a disease that occurs more frequently in Asia. We're working with the Jean Perrin Center at Clermont-Ferrand University Hospital in France, and that collaboration will assess CGP's clinical value for late-stage patients, with the current standard of care serving as the comparison. Oncology more broadly: GRAIL continues to see robust momentum. The Galleri test arrived from GRAIL last year, and it holds the distinction of being the first clinically validated multi-cancer early detection test offered to patients and providers. Galleri can pick up over 50 cancer types, and the majority of them lack any screening option today. We're very pleased with how the market has responded so far. A number of big employers and payers have taken up Galleri, and we have more than 1,500 prescribing partners, among them major health systems like the NHS, the Mayo Clinic and the Cleveland Clinic. Our team continues to work with pharma partners — AstraZeneca, Amgen and Bristol-Myers Squibb — on possible new innovations in the post diagnostic space. And finally, we find the recent programs introduced in the U.S. and the EU to beat cancer quite encouraging. Both the U.S.' Cancer Moonshot National Initiative and Europe's Beating Cancer Plan reflect a growing recognition that early detection is a crucial part of the fight against cancer. Illumina remains firmly dedicated to backing every initiative in early detection, oncology testing, and treatment that aims to enhance care and save lives. Past oncology, reproductive health also posted a robust year in 2021, fueled partly by updated American College of Obstetricians and Gynecologists, or ACOG, guidelines that expanded genetic testing coverage to all U.S. pregnancies, along with growing global uptake of our VeriSeq NIPT V2 product. Our third clinical market, genetic disease testing, experienced enormous growth and further evidence generation in 2021, highlighted by major publications in both the New England Journal of Medicine and JAMA Pediatrics confirming the clinical utility of whole genome sequencing, or WGS, for critically ill children. During 2022, coverage has been growing—Medicaid programs in California, Oregon, and Maryland have started covering WGS for infants in the NICU. Programs for WGS in NICU settings are expanding around the world as well, such as our recent collaboration with Germany's Hannover Medical School to bring WGS into use for NICU patients. That project adds to the mounting evidence—from other nations like the United Kingdom and Australia, and from states throughout the U.S.—demonstrating that WGS delivers substantial advantages when diagnosing genetic disease in critically ill newborns, while also producing cost savings for health systems. Now looking at our research and applied markets: consumables rose 43% during 2021, fueled by efforts such as All of Us and sustained COVID monitoring work, which together added roughly $220 million to total revenue. Let me take a few minutes to discuss three major trends that will fuel growth over the long term. The first is the ongoing deepening and broadening of the markets Illumina can serve. Greater access and uptake are driving additional penetration of the markets we already serve. Sequencing use is expanding around the world across many applications, and fresh initiatives keep bringing genomics into national health care systems. Our technology and genomics know-how are powering initiatives such as Our Future Health — the biggest health research effort the UK has ever undertaken — which will provide genetic analysis of DNA samples drawn from as many as five million volunteers. That data is going to fuel all sorts of potential discoveries, among them new signals that allow earlier disease detection, fresh approaches for better predicting which populations face high risk of disease, and new personalized therapies or tools aimed at delaying illnesses or altering how they progress. We're thrilled to be part of this project, serving as the genotyping partner for the program. We also keep backing an expanding worldwide COVID surveillance network that is set to reach into broader pan pathogen and genomic epidemiology efforts. That infrastructure is already being put to work studying other infectious diseases. In South Africa, for instance, the team led by Dr. Tulio de Oliveira at CERI, the Center for Epidemic Response and Innovation, is deploying its fleet of sequencers to investigate other communicable diseases such as HIV and malaria; we anticipate further epidemiology application opportunities down the road as worldwide funding for pathogen surveillance and research grows. Meanwhile, new sequencing applications and opportunities are expanding and evolving quickly, including across several nascent areas like multi-omics and drug development. We're backing the full spectrum of multi-omic applications on our instruments, among them proteomics, where our co-development partnership with SomaLogic has gotten off to a strong start.
Francis deSouza
executiveWe're also fueling expansion in the drug discovery space, since genomic-based methods have the potential to greatly improve timelines to market, success probabilities, and expense. In addition to the partnership we have with Nashville Biosciences, we're collaborating with the Montreal Neurological Institute Hospital, Takeda, and Roche so that patient data can be analyzed at large scale and promising targets for neurological disease drug development can be pinpointed. Efforts like Our Future Health, a rising number of applications, and broadening worldwide access will underpin NGS adoption over the long term. The fresh markets we're unlocking, such as drug discovery, will drive further adoption while also advancing data equity and the embedding of genomics within health care. As we head into 2022, demand for genomics is climbing, and our instrument backlog stands at almost twice the level it was at when we entered 2021. Another pattern we're seeing is expansion across multiple dimensions of our customer base. Those already with us are adding more instruments to their fleets. At the same time, a rising count of customers are coming to Illumina for the first time. Because of this, by the close of 2021 our installed base had reached over 20,000 instruments. A third pattern involves demand for generating ever more data. During 2021, a typical Illumina high-throughput customer produced roughly four times the data it had in 2017. That trajectory will hold as customers seek fuller genomic information and next-generation sequencing turns into the norm in clinical environments. Because multiple tests get run on each patient and samples feed into high-intensity uses such as multi-omic, these changes will raise project counts, samples per project, and sequencing depth per sample; that push for greater throughput will keep fueling additional expansion of our sequencing consumables revenue. In 2021, over 80% of our revenue across consumables and services is recurring; a more predictable and more profitable stream like this gives us a tremendous foundation for investing in the business and generating future growth. The results Illumina delivered in 2021, together with the considerable momentum we carry into 2022, show how well positioned we are to serve our customers and partners as these trends speed up genomics' role in health care. At this point I'll hand the call to Sam, who will walk through further specifics on our results and operations and also cover the guidance we're giving for 2022. Sam?
Sam Samad
executiveThanks, Francis. As a quick reminder, GRAIL's consolidated financial results are part of our fourth quarter numbers. I'll start by reviewing those consolidated results, then cover segment results for core Illumina and GRAIL, and wrap up with our 2022 outlook. The figures I'll be calling out are non-GAAP results, which include stock-based compensation. Please take a look at the GAAP reconciliation for these non-GAAP measures, which you'll find in today's release and in the supplementary data posted on our website. Fourth quarter revenue was a record and again exceeded our expectations, driven by continued strength in our core business, with consolidated revenue rising 26% year-over-year to $1.198 billion. For Q4, GAAP net income came to $112 million, equal to $0.71 per diluted share. Non-GAAP net income stood at $117 million, or $0.75 per diluted share; that figure reflected $0.66 of dilution stemming from GRAIL operating losses plus $0.09 of additional dilution tied to the 9.8 million shares issued to fund the GRAIL acquisition. Our non-GAAP tax rate was 15.6%, a decrease of 280 basis points from a year earlier, driven mainly by a more favorable earnings mix across jurisdictions that carry lower statutory tax rates. Weighted average diluted shares for the quarter totaled roughly 157 million. Turning now to segment results, I'll begin with the financial performance of core Illumina. Core Illumina's revenue rose 25% from a year earlier, reaching $1.193 billion. That was fueled by yet another quarter of record shipments across both clinical and research, with particularly notable momentum in oncology testing, genetic disease testing and population genomics. Core Illumina sequencing consumables revenue climbed 32% year-over-year, hitting $792 million, powered by record NovaSeq consumables shipments that stemmed from substantial installed-base expansion along with robust pull-through, which once again came in above our guidance range. For core Illumina, sequencing instruments revenue was up 35% year-over-year at $191 million, propelled by record NovaSeq shipments thanks to continued adoption of new to high throughput customers and accelerating demand in oncology testing. Shipments of NextSeq 1000 and 2000 units hit a fresh peak during the quarter, and every one of our mid- and low-throughput systems posted solid year-over-year gains. As we head into 2022, our sequencing instrument backlog is robust—nearly twice what it was when we entered 2021. Once again, COVID-19 surveillance revenue came in above what we had anticipated, fueled by ongoing attention to variant tracking following the arrival of the Omicron variants. In the fourth quarter, COVID-19 surveillance accounted for roughly $42 million of sequencing consumables revenue along with $8 million in incremental instrument revenue. Core Illumina sequencing service and other revenue totaled $106 million, unchanged from a year earlier, since growth in instrument service contracts and lab services was canceled out by reduced IVD partnership revenue. Now looking at core Illumina's performance by region: the Americas brought in $619 million in revenue, a 25% rise from the same period last year. That growth came from clinical demand in oncology testing, strong genetic disease research activity among pharma customers, population genomics efforts such as All of Us, and COVID surveillance testing. EMEA generated $350 million, up 23% versus a year ago, powered by emerging markets, population genomics programs, and COVID surveillance testing. Greater China revenue hit $121 million, 26% higher year-over-year, as clinical momentum there continues thanks to an ever-growing hospital installed base. APJ brought in $103 million in revenue, which is up 34% from a year ago, driven by record NovaSeq placements as well as continued momentum in clinical markets such as genetic disease testing and oncology testing. Moving on to the other core Illumina P&L items. Non-GAAP gross margin for Core Illumina reached 71.6%, a 470 basis point improvement year-over-year, largely attributable to improved fixed cost leverage resulting from higher volumes. Core Illumina non-GAAP operating expenses were $580 million in total, up $141 million versus the prior year, chiefly due to growth in headcount, increased performance-based compensation costs, elevated onetime expenses tied to partnerships, and more project spending arising from R&D and operations investments that underpin the growth and scale of our business. Non-GAAP operating expenses exceeded what we had expected this quarter, driven by higher-than-anticipated variable compensation and partnership costs. At Core Illumina, non-GAAP other expense totaled $8 million, which was $28 million under the other income recorded in Q4 2020; that gap reflects reduced interest income from short-term investments we liquidated to fund the GRAIL acquisition, plus interest expense tied to the term notes issued in Q1 2021. Turning now to GRAIL's results: quarterly revenue there reached $10 million, comprising Galleri test fees along with MRD partnership revenue. GRAIL's non-GAAP operating expenses for the quarter were $131 million, primarily reflecting costs associated with headcount and clinical trials. Turning to our consolidated cash flow and balance sheet items. Operating cash flow came in at $282 million. DSO was 49 days, compared with 50 days in the prior quarter, which reflected revenue linearity. Capital expenditures for the fourth quarter of 2021 totaled $70 million. Free cash flow was $212 million. During the fourth quarter, we did not buy back any common stock. We ended the quarter with approximately $1.3 billion in cash, cash equivalents and short-term investments. Now shifting to our 2022 guidance. For the full year 2022, we anticipate consolidated revenue growth of 14% to 16%, which would put us at roughly $5.16 billion to $5.25 billion. For full year 2022, we expect Core Illumina revenue to grow 13% to 15%, reaching approximately $5.11 billion to $5.2 billion. For 2022, GRAIL anticipates revenue between $70 million and $90 million, mostly from the Galleri test; at the midpoint of our revenue guidance range for fiscal 2022, we anticipate Core Illumina sequencing revenue will increase roughly 15% compared with the prior year, powered by rising demand in our base business. That figure includes about $25 million in intercompany sales to GRAIL, which get eliminated in consolidation. We anticipate Core Illumina sequencing instrument growth of about 10% year over year, fueled by sustained momentum in NovaSeq and NextSeq placements. On Core Illumina sequencing consumables, we foresee growth of approximately 18% compared with last year, propelled by a growing installed base of instruments as well as strong utilization among our customers. We think that momentum is going to allow us to continue expanding the platform, and we are raising our NovaSeq pull-through forecast to a range of $1.2 million to $1.3 million for each system in 2022. When it comes to NextSeq 1000 and 2000, our expectation for pull-through is $130,000 to $180,000 for each system in 2022. NextSeq 550 pull-through ought to come in somewhere between $100,000 and $150,000 for each system. For MiSeq, we are expecting pull-through of $35,000 to $45,000 for each system. And for MiniSeq, the pull-through we expect falls in a range of $20,000 to $25,000 for each system. COVID surveillance revenue should land somewhere between $130 million and $150 million in 2022. Consolidated non-GAAP operating margin is anticipated to come in at 15.5% to 16%, while Core Illumina non-GAAP operating margin should be approximately 28% for 2022. We also anticipate a consolidated non-GAAP tax rate of about 19%. Consolidated non-GAAP earnings per diluted share should fall between $4 and $4.20, and that figure includes GRAIL dilution of $3.75 — specifically about $3.25 from GRAIL's operating loss dilution plus roughly $0.50 of incremental dilution tied to the 9.8 million shares issued to fund the GRAIL acquisition, consistent with what we said before. Lastly, diluted shares outstanding for fiscal 2022 should be about 159 million shares. Turning to the first quarter of 2022 for consolidated Illumina, revenue is expected to rise 10% to 12% year-over-year compared with the first quarter of 2021. This represents a quarter-over-quarter improvement from Q4 2021, showing we've gotten off to a solid beginning this year. We expect non-GAAP operating margin to rise about 300 basis points on a sequential basis, primarily because operating expenses will be lower. For the non-GAAP tax rate, we anticipate it will be in line with the roughly 19% we guided to for full year 2022. Diluted shares outstanding are expected to come in around 159 million, matching our full year 2022 guidance. At Core Illumina, the Q1 non-GAAP operating margin should track our full year 2022 guidance of approximately 28%. With that, I'll hand the call back to Francis for his closing remarks.
Francis deSouza
executiveThanks, Sam. In closing, I want to express gratitude to our teams, our partner network, and the remarkable scientists and clinicians we serve. I'm tremendously excited about the many opportunities that lie ahead. At present, over 1 billion people worldwide have coverage for genomic testing, and we anticipate that figure will double in 5 years as genomics speeds up adoption and expands the potential of personalized medicine. Illumina will keep supporting the rising number of patients across the globe who access genomics' life-saving advantages — from oncology therapy selection to reproductive health, genetic disease testing, and pathogen surveillance. We'll also keep advancing genomics into new frontiers such as drug development and proteomics. In addition, we will enable discovery across these existing and new markets through a pipeline of innovative products and solutions created together with our customers; it has been wonderful to witness the strong interest and enthusiasm throughout our customer base for our newest developments, among them our breakthrough Chemistry X and our Infinity long-read technology. We anticipate that we will not only directly address unmet market needs but also revolutionize how scientists and clinicians connect spectrum sequencing. Together, we're enabling genomic-based discoveries capable of transforming health care and ultimately delivering a brighter future for human health. I'll now ask the operator to open the line for Q&A. Operator?
Dan Brennan
analystThanks a lot, and I appreciate your taking the questions. Obviously, congratulations on the quarter. My question concerns the new products. Clearly, we'll be hearing much more about this in the fall. But you'd expect there to be material interest in Chemistry X and Infinity, especially with some of the anticipated competitive launches coming between now and roughly HBT. So I'm just wondering — you've laid out some basic metrics on relaying to accuracy and speed, and you've talked about revolutionizing things and unmet needs; so, Francis, I was hoping you could give us a bit more color on how we should think about these products? Of course, you won't be sharing new factors with us right now, but I'm curious about the unmet needs that could be tackled and/or this notion of revolutionizing things, since one could argue Illumina has done a wonderful job evolving their product lineup, pushing higher throughput and lower prices — yet "revolutionary" feels like quite a strong word for this product. So I'm wondering and hoping we might get a bit more detail. Thank you.
Francis deSouza
executiveYes. Thanks, Dan. And as I mentioned, it's been wonderful to see how our customers have responded to both Chemistry X and the data we've shared so far on Infinity. Let me walk through each one briefly. With Chemistry X, we've kept everyone informed over the years as we went from research into product development and shared some of the early data, roughly a year ago or a bit more. Then, as I mentioned a couple of weeks ago, Chemistry X is now shifting from product development into manufacturing, with an entirely new manufacturing facility and the scaling up of production. So it's been wonderful to watch the progress and the innovations contained in Chemistry X. To reiterate, this represents a complete reimagining of our chemistry from scratch—likely the most significant leap forward in our chemistry since Solexa came into being all those years ago. For our customers and for the industry, what this means is that we anticipate a dramatic shift in chemistry speed, which will result in substantially quicker turnaround times for the tests our customers are conducting. That matters a great deal not only for really big research efforts but particularly in clinical environments, where the goal is to deliver some of those findings to patients faster; it translates into greater precision, and all of that together also opens up a genuinely exciting path when it comes to price per G. As we've said before, we remain dedicated to pushing sequencing costs lower so it becomes more widely accessible, and Chemistry X plays a core role in that. So at this point we're moving into manufacturing, and we're nearer to launching it in products than at any prior time. I've said before that this is going to be foundational for every new product we launch; and when we look at our current portfolio, there's no reason why it wouldn't make sense for certain parts of it to include this as well. As for Infinity, the excitement comes from the way we've rethought how people approach long reads and short reads; and once again, we returned to first principles to say that what customers don't want is two separate platforms — one for short read and another for long read. The message they're conveying is that they'd like to bring several of SBS's greatest strengths — high accuracy, low cost, and low input requirements — over to all reads. So in rethinking long reads, we retained some of those finest elements: minimal input needs, reduced cost, and keeping accuracy high. They also want it to work as a single molecule approach rather than a composite of multiple molecules. And so the team has done a fantastic job innovating to deliver that with our Infinity technology. You've already gotten a look at certain figures from a number of our clients. As we've said, we plan to launch it commercially before this year is out, and additional figures along with further details will continue coming your way from us.
Tycho Peterson
analystHey, thanks. Regarding guidance, 10% sequencing instrument growth—I was hoping you might add a bit more detail there. Clearly, you have the NovaSeq DX launch coming. How significant do you expect that to be? And then Francis, picking up on what you said a minute ago, how do you keep from freezing the market before Chemistry X gets rolled out? And then a follow-up on the GRAIL guidance as well—$70 million to $90 million is a big step up from $10 million in the fourth quarter. So could you talk a little about the scale-up plans and how you intend to get there?
Sam Samad
executiveYes. Maybe I can begin, Tycho—this is Sam. Thanks for asking about the instrument guidance, and I’ll offer just a couple of quick remarks. First of all, let me say that instruments in 2021 delivered incredible performance; we’re now entering 2022 with a record backlog of instruments. That gives us considerable confidence in the guide, the 10%. When we think about some of the drivers behind it: continued very strong placements of NovaSeq, continued very strong placements on the mid-throughput side with NextSeq 2000, 1000. And we discussed in 2021 the record performance across those two platforms; now there is a headwind, which is COVID surveillance. We placed quite a few instruments for COVID surveillance in 2021. And frankly, we don’t expect to place instruments for COVID surveillance in 2022. So that’s a year-over-year headwind factored into the 10% growth in terms of the guide; for NovaSeq DX, that’s a product we’re very excited to launch; it will launch later this year. It does not represent the material impact in terms of growth for instruments in 2022; so Francis, maybe...
Francis deSouza
executiveYes. So let's talk about Chemistry X — what it delivers for our customers, and how we might prevent the market from freezing up, as you put it. One thing customers find exciting about working with Illumina is being part of this great roadmap: they don't just get what we offer today, they also know we'll keep innovating and launching new products. So for our customers, watching Chemistry X take shape on this journey has been exciting, and I think we've done a good job sharing data throughout the entire process. That way they know what's coming and can get a sense of what it might mean for them. Since we haven't announced a new product, there's no reason for the market to pause and wait. Our customers are also aware that they've been through this process with us multiple times—whenever we launch something new, we have programs ready that cover trade-ins, or if an order is already in our backlog, they can move it over to the new instrument if that's what they prefer. So over the years, we've built up quite a few solid programs designed to give our customers a smooth upgrade path. Additionally, another insight we've gained—particularly within clinical markets—is that when a new instrument is launched, some of our customers typically purchase a single unit of the new instrument, for instance, and utilize it to develop their new workflows and become acquainted with the new instruments, after which they plan an upgrade across a multiyear period. So that scenario could still unfold. Yet as we bring a new instrument to market in the future, they might buy one to become comfortable with it, and then leverage that to plan and upgrade across a multiyear period; and then regarding GRAIL, the momentum we're observing with GRAIL has been terrific to watch. They're getting traction with employers, as we mentioned. The interesting part is that while we anticipated uptake among financial services firms, tech companies, and others that typically take a progressive stance on leveraging benefits to draw talent, what's genuinely exciting is that customers are coming from every industry. As we noted, we've got major logistics and transportation companies that have committed to providing this benefit to their staff, which has been great to watch; and we're equally happy about how many prescribing providers now have hands-on familiarity with the Galleri tests. We mentioned that more than 1,500 prescribing providers ordered the test in 2021—last year—as we moved into this year. That gives us a solid group of health care professionals who now have some familiarity with Galleri and ought to feel more at ease ordering it as we go forward. As for the guidance, the bulk of the forecast for Galleri—for GRAIL this year—is Galleri. A portion of it does relate to MRD, although that share is smaller. Looking at that number, there could be some potential upside, and we'll keep watching the momentum they're building in that area.
Dan Arias
analystGood afternoon, everyone, and thanks. Francis, I'd like to return to Chemistry X briefly. Could you tell us more about the per-gigabase economics that may come into play? How much lower do you believe genome pricing could go for the NovaSeq crowd? And for users at mid and lower throughput, should those people also see sequencing costs drop if they run a NextSeq or a MiSeq? Then, if I may squeeze in a second question: regarding the Nashville Biosciences collaboration, what's the timeline for those 250,000 samples you're sequencing there, I believe? And is all of that whole-genome? Thanks.
Francis deSouza
executiveYes. Let me begin by discussing Chemistry X and its potential implications. When you compare Chemistry 1 with Chemistry X on a straight apples-to-apples basis, you'll achieve substantial cost savings as you <<inaudible>> at this point. In the end, that outcome hinges on all the other factors we believe <<inaudible>>, so ultimately the cost per key will be driven partly by chemistry; that means we also need to consider optics <<inaudible>> and everything along those lines. It's somewhat premature to commit to the precise impact. That depends on <<inaudible>> it hinges on the full oncology <<inaudible>> we were specific about what that delivers to you in specifics <<inaudible>> the price; however, we will be extremely confident that a major portion <<inaudible>> of the cost reduction comes from chemistry. There's one more particular point to add here — Nashville, as that gets brought in.
Francis deSouza
executiveYeah. On Chemistry X, the short version from me is that this represents a major move ahead when it comes to bringing prices down and when it comes to sequencing for our customers. That said, the exact figure is going to hinge on which kind of instrument we put it into, along with the rest of the components from the technology ecosystem that we incorporate into that instrument. The data path, the optics, and so forth. So keep watching — as things become more concrete, we'll pass that along to you.
Vijay Kumar
analystNice work on the quarter — I'd like to dig into the guidance. Sam, your Q1 revenue outlook shows sequential growth. Historically I don't believe we've seen that, and the guidance implies a build quarter by quarter through the year. Could you speak to the visibility behind that? I know you mentioned backlog is twice as high; so talk through what visibility you have into the guided efferent. On the $70 million to $90 million for GRAIL, is that the gross contribution? Does some intercompany elimination sit inside that figure? Or is it a net number? And is that a proxy for Galleri volumes? Thanks.
Sam Samad
executiveSure — thank you, Vijay. I'll take on both of those questions, starting with the guidance. Our visibility into the guide is solid. The guide, I'd say, is balanced, and we have a lot of confidence in hitting the numbers we've laid out. On your first question, you've got it right. We're coming into the year with a lot of momentum in Q1. The business genuinely is very strong. Momentum on the clinical side is very strong — oncology testing, genetic disease testing, NIPT — and our research markets are robust as well. Our backlog is very strong; as we mentioned, it's actually a record backlog when it comes to instruments. That's really what's fueling the Q1 momentum. Looking forward to the coming year, we expect a pattern that's more linear — closer to what we saw before the pandemic, with sequential revenue building or rising as the year progresses. A few items we've taken into account in the guidance are baked into that 14% to 16%, Vijay, and we think they also reduce the risk in the guide. Let me walk through a couple of them. One example concerns COVID surveillance. As I said in the prepared remarks, we're assuming $130 million to $150 million of COVID surveillance revenue. That represents a step down from last year. We're roughly at the halfway mark, with a decline of about $80 million. We've likewise accounted for a reduction in population genomics, which stems from the UK Biobank coming to an end—its completion and wind-down. That means a year-over-year decline in population genomics revenue. Meanwhile, NovaSeq is demonstrating exceptionally robust pull-through. As we noted, in 2021 we exceeded $1.3 million per instrument, and we're now providing a pull-through guidance range of $1.2 million to $1.3 million. This accounts for the substantial instruments joining the installed base, which will require some time before reaching the pull-through levels we saw on average in 2021. Overall, we have strong confidence in the guidance, with solid visibility. Underlying all of this is the fact that we remain in a pandemic year—now in year three—with the uncertainty that entails. Regarding GRAIL, the $70 million to $90 million figure reflects end GRAIL sales to their customers. There is indeed an intercompany revenue elimination that impacts our consolidated Illumina revenues overall. That said, the $70 million to $90 million figure represents total end sales by GRAIL to its customers, and intercompany activity has no bearing on it. What we sell to GRAIL shows up within the core business, and those amounts are then removed at the total consolidated level.
Derik De Bruin
analystHello, good afternoon. Thanks for taking my questions. I have two questions that are related. First, about the new platform you're hinting at: will you follow a HiSeq X style approach and basically split it up, targeting applications such as whole human genome or single cell? Or will you make it available broadly? And then, as a follow-up: I can definitely see demand elasticity in the research market — I mean, that has clearly been demonstrated. But what assumptions are you making about the clinical market as you bring the price down? What are your volume assumptions, roughly? I mean, don't you have to keep clinical pricing kind of at a premium for a while longer before you can really see the volumes in there to make up for it? Thanks.
Francis deSouza
executiveGreat. Thanks, Derik. So let's take both. This new chemistry can be applied across the throughput spectrum. So all options at this point are on the table. There are options, like you said, where we could create an instrument that targets a, and catalyzes a segment of the market. As you're pointing out, HiSeq X proved incredibly effective in unlocking the entire genome sequencing market — prior to that instrument making a $1,000 price point possible, whole genomes accounted for only a very small slice of the market. Following HiSeq X, there was simply an explosion in how many customers were able to perform whole genome sequencing, and who in fact went ahead and did it. So one possibility before us that Chemistry X would make feasible is, once again, to seek out chances of that kind to catalyze particular segments of the market. There are, of course, plenty of market segments one could imagine being catalyzed. Take, hypothetically, the single cell market as an example. Many, many customers tell us they would be thrilled—truly thrilled—to run far, far larger experiments using single cells. Something like Chemistry X could open up that portion of the market. Customers also tell us they would be delighted to conduct much, much bigger experiments aimed at identifying and understanding the genomic drivers behind neurological conditions such as autism, Alzheimer's, and Parkinson's. So it's easy to picture this enabling some of those types of experiments. It really hinges on which applications we choose for this chemistry. The advantages include reduced expense, plus quicker processing—since another gain from this chemistry is the possibility of delivering results at particular depths to customers inside one shift. That could be genuinely transformative for some clinical uses. So, provided pricing doesn’t change at all, merely delivering answers inside a single eight-hour shift might unlock opportunities in particular market segments. When we look at pricing through the customer's lens, certain parts of the clinical market have already gotten to the stage—thanks to our end-to-end offerings—where buyers pay for the product on a per-report or per-sample basis. Areas like NIPT, for example, along with genetic disease diagnosis, are already enabled at their current price points. So there's no reason to adjust the per-sample price, since reimbursement already exists, and that allows our lab customers to operate profitably in those segments. That said, there are other clinical markets in which a lower price point would be fundamentally enabling; so that's roughly how we're weighing the options in front of us with Chemistry X. Operator, we're set to take the following question.
Kyle Mikson
analystGreat, and thanks for the question. It's really a two-part one. So a lot of these newer short-read platforms are coming to market soon with throughput in the low-to-mid range, which fits the clinical market—things like hospitals and clinical research. I'm just wondering whether that will be an early focus for you, since it might lead to some clinical market share or growth in the near to medium term in that part of the market that's kind of underpenetrated right now. Then for the second part, Francis, you mentioned earlier that the Biden administration launched the cancer Moonshot initiative, and it references multi-cancer early detection testing, particularly involving studies or trials to accelerate development and market adoption of that test. So I'd just like to get a sense of how confident you are that the initiative will move the needle for the MSAID industry overall. And importantly, could it improve how the merger is perceived domestically or globally, specifically with obviously, and potentially have any downstream impact on the ongoing trials or reviews? Thanks. <<inaudible>>
Kyle Mikson
analystSure, can you hear me?
Francis deSouza
executiveWe can.
Kyle Mikson
analystGreat, that actually bundles two questions together. To start with the first one: a lot of these newer short-read platforms that are either about to launch or that offer low to mid throughput are targeting the clinical market, and that will likely be an early priority for these up-and-coming firms. So I'm curious whether you believe that could erode your clinical market share or growth over the near to medium term, especially since that area remains fairly underpenetrated? Then my second question concerns GRAIL and the cancer Moonshot initiative that the Biden administration recently announced, which referenced multi-cancer related action tests. What I'd like to grasp is whether you expect the industry to really move the needle for the MSAID industry as a whole. And might it boost how the merger is viewed domestically or globally in particular, and possibly affect in any way the trials or reviews currently underway?
Francis deSouza
executiveAll right. We’ll take both. The first question concerns new entrants in the low- to mid-throughput market and how we anticipate that will unfold. Let me start there. I’ll say, clearly, we have excellent products in that segment of the market. And just over the past couple of years, we launched the NextSeq 1000, 2000, which are aimed squarely at that space. We believe those offerings fit clinical settings particularly well, since from a clear standpoint the MiSeq Dx and NextSeqDx are already workhorses in that market. Add to that the outstanding price performance delivered by the NextSeq 1000 and 2000. Those instruments — the NextSeq 1000 and 2000 — are the strongest mid-throughput products available today, even when you factor in some of the newcomers entering the space, and I expect they will keep delivering highly compelling value to our customers down the road. Another notable trend we're observing in the marketplace is that an increasing share of new buyers are entering at the premium tiers of our portfolio, which is a shift from what we've traditionally witnessed. What's happening in the market, then, is that the workloads emerging for sequencing tend to be heavier on data and heavier on sequencing itself. These are high-intensity use cases, and they're simply calling for greater sequencing throughput and more compute capability. The implication, I believe — and we witnessed this unfold in the computer with the PC market, and we saw it happen with iPhones — is that devices simply have to become increasingly powerful. To be honest, I'm the one making the case that NovaSeq represents the next MiSeq — and I believe that captures the ethos we're observing in the market: demand for greater power keeps growing without limit. If you're aiming at what counts as low- and mid-throughput today, you had better arrive with substantial power, because tomorrow's low and mid throughput segments will look much more like the high throughput market of today. On GRAIL and the Cancer Moonshot, greater national focus on cancer and on bending the mortality curve is plainly a good thing, so it's wonderful to see. It's especially exciting to hear recognition that detecting cancer early. And more specifically, catching multiple cancers at once through a simple test, represents a key part of this battle against cancer. And so the spotlight being placed on this area, I think, is fantastic to observe. We'll be watching to see how that unfolds when it comes to extra funding or faster regulatory review or reimbursement. But we believe it's all quite beneficial for speeding up that market. It's clearly particularly beneficial for GRAIL, since GRAIL is the sole product available in the market today capable of detecting 50 cancers and identifying tissue of origin; so that's obviously very exciting from a GRAIL standpoint.
Sung Ji Nam
analystHello, and thanks for taking my question. Regarding the GRAIL multi-cancer MRD test that you're planning to launch next year — I was curious whether you could share some thoughts on how its performance characteristics compare with the single-cancer MRD tests currently on the market. Also, should we anticipate possible interim data readouts at points during this year?
Francis deSouza
executiveYes. The final performance characteristics will, of course, be disclosed when the product is launched. But with the approach GRAIL is taking, here are a few things we already know, along with a few things to keep an eye on. First, since it draws on the same underlying technology as the Galleri test, this is a test capable of detecting recurrence across multiple cancer types, rather than just one. That's genuinely useful, because the cancer that shows up sometimes isn't the exact same cancer the patient had previously. GRAIL's approach will therefore be able to catch that. Second, because you don't first need a tissue biopsy in order to create the test for a patient, you should also be able to get the test to the patient considerably faster than would be the case with an approach requiring a tissue biopsy. So another key metric to watch — one that matters a great deal for some patients — is how quickly a patient can obtain that test and have it ready for them. From that standpoint, the GRAIL approach is, conceptually, simply much faster; that's another key metric to watch for. Then, when it comes to how the Galleri test performs — its sensitivity and specificity for early detection are really strong. Its false-positive rate is extraordinarily low; and since the MRD test will be drawing on that same technology, that's something to watch for as well — they're bringing substantial expertise in delivering this screening test with high positive predictive value into the MRD market.
Sung Ji Nam
analystYes, thank you.
Puneet Souda
analystThanks. Hi, Francis and Sam. I appreciate the two of you taking my question. I'll merge two questions into one. First, I realize you've already answered a fair number of questions about Chemistry X, but I just want to verify that the same benefit applies equally in every application — genome, exome, routine RNA seq, single cells. I just want to be certain of that; and then, does it get us closer to a $100 genome, or does it push the $100 genome significantly below what a genome costs today? And finally, I just want to clarify something about the 10-kilo base reads you're getting with Infinity — is that core technology still SBS? That's how I understand it. So in the end, is this — does this sit at the lower end of what native long reads generate in terms of long-read sequencing read lengths? So should we think of it as synthetic? I just want to confirm we're framing that the right way. Thank you.
Francis deSouza
executiveYes. Puneet, let me address your questions one by one. First, Chemistry X. Is it limited to a single application, or does it function across every application? The answer is that it functions across every application. This chemistry isn't tied to any particular application. So you should — you'll see the advantages of this chemistry in any application you run on a sequencer that employs it. It’s definitely a major move ahead when it comes to lowering price. So based on the form factor and based on the instrument we release, it will be able to provide a reduced cost in that segment of the market. And again, it’s one component. As you know, chemistry is one part of it, but it’s a part that’s going to give us a major move ahead no matter which form factor we select to release this chemistry and no matter which instrument type; regarding Infinity, it is SBS, and one of the things customers have told us loudly is that they want a single platform capable of scaling read lengths up and down. What labs reject is having several separate technologies, each with its own upfront workflow, forcing different technician training and varying DNA input requirements. A major demand here, then, is whether you can offer one chemistry and one platform that scales both up and down—and that is exactly what Infinity provides. It runs on SBS, so you get every capability you already recognize and are comfortable with through SBS. For the 8,000 clients we serve and the 20,000 instruments deployed in the field, that is genuinely excellent news; as for the 10 kb, frankly it isn't a loan at all, and it lines up precisely with where certain other long lead competitors sit in the market. A few may indeed go past that level, yet most of the market isn't located there.
Puneet Souda
analystUnderstood. Thanks.
Tejas Savant
analystHi everyone. Good evening. Francis, I've got two questions for you. First, just to clarify something on Chemistry X — I believe you said earlier that you may extend it to certain portions of the existing portfolio as well. So I'd like a finer point on that. Does that mean it could be backwards compatible, at least on a selective basis? And then the second one concerns the GRAIL guidance. Would it be fair to assume roughly 85,000 tests at the midpoint using that list price of about $950? Or does your guidance assume a lower effective ASP?
Francis deSouza
executiveYes. Thanks for that. I'll address the first question. What I said is that all new platforms going forward will use Chemistry X. But to your point, there's no technical reason we couldn't selectively bring Chemistry X to portions of the current portfolio; we haven't announced any plans around that at all, but from a technical standpoint it is absolutely backwards compatible for some portions of our portfolio; and then the GRAIL...
Sam Samad
executiveI'll take that one, Francis. So on GRAIL, Tejas — and thanks for the question, by the way. No, I wouldn't assume that, actually. The price is, as you mentioned, roughly in the $950 range. But I wouldn't assume that this price holds uniformly across the entire guide or the total revenue guide, since pricing assumptions could differ depending on the collaborations and partnerships they have in place. So I wouldn't make that assumption when it comes to test volume.
Francis deSouza
executiveTejas, is that enough to answer your question?
Tejas Savant
analystYeah, I'm all set. Thanks.
Patrick Donnelly
analystHi everyone. Appreciate you fitting in the questions; this one may be directed at you, Sam. On the backlog side, it's clearly encouraging to hear it's nearly twice what it was at the start of last year. Could you speak to how much of that reflects a natural organic build as the numbers grow versus any supply chain challenges — I'm sure that was a major topic a quarter ago? Do you feel you're largely beyond the worst of it, and what should we expect over the coming couple of quarters? Has it settled down somewhat for you?
Sam Samad
executiveYeah. I'd say the straightforward answer, Patrick — and thank you for asking — is that it really is organic build. It comes from the strength of the business. It comes from the demand strength we're seeing in clinical and in applications spanning clinical and, to some degree, research. And part of that backlog consists of instruments. Part consists of consumables. So it — it mirrors the broad base of our business. On supply chain, to get to your question, I mean, as we discussed last quarter, supply chain is clearly more complex nowadays with the pandemic, with COVID; but we've undertaken many steps and pursued many initiatives aimed at preserving continuity in the supply chain, at ensuring customers have uninterrupted product access. So we really haven't encountered supply chain disruption, thanks to some of those actions, apart from very isolated cases of the kind we typically see, but nothing out of the ordinary when it comes to supply chain disruptions; we've ensured we raised the distribution center capacity we hold, we've raised safety stock on consumables. We've taken many steps to guarantee the supply chain's integrity holds up and that we can get product to customers. So I just want that to be clear.
Luke Sergott
analystGreat, and thanks for taking the questions. Could you bring us up to date on the EC deadline suspension and what that ultimately amounts to? Then, as you both go through the timelines in the appeals process, give us a sense of how you could see that unfolding if things don't go your way and you then appeal — again, just from a timing standpoint. And finally, I'd like to get a picture of the margin characteristics here across the year and in the guidance, and really how we ought to think about the pacing there?
Francis deSouza
executiveYes; I'll take the first question, which is about how the various regulatory processes now underway are timed. First, on our Phase II review with the European Commission, we're currently at the point where talks are happening regarding possible remedies that might work for this deal. So the pause we're in at the moment gives both of us, both sides, time to sort of work through that and discuss possible remedies together. And what that means is it stretches the time line out a bit. At the beginning, the time line was that we anticipated a decision by the end of March. It appears that call will now land in Q2. Separately, there are other proceedings underway in Europe — a case in Luxembourg examining the jurisdictional questions tied to this matter. A ruling there is likewise expected around the Q2 window. So we'll be keeping an eye on it. The hearing took place in Q4, and we await a decision within that period. That's the timeline for the European proceedings. Should either one come out in our favor, the European portion of the process is finished and we can begin integrating. Should the review come back against us, an appeal mechanism remains available that we could explore once that ruling is issued.
Sam Samad
executiveYes. And Luke, on the question of how margins will evolve over the course of the year, we'll share further updates on that as time goes on. We've given you an update on Q1 and on our guidance for Q1 where operating margins are concerned. We noted that for Q1, on a consolidated Illumina basis, there will be a 300 basis point sequential improvement from Q4, and we said core Illumina in Q1 would come in at approximately 28%. Now, looking ahead, we don't typically make quarterly margin comments of that sort, but we'll offer additional updates as the year progresses — as we get further into the year.
Luke Sergott
analystAll right. Thanks.
John Sourbeer
analystHello, and thank you for fielding my questions. In the presentation you gave last month, I believe you mentioned that roughly 40% of mid-throughput customers are in clinical at present, and I think it's a comparable figure for low throughput. Do you have any views on how 2022 is shaping up for those? And how long does it take to reach a 50-50 split there?
Francis deSouza
executiveRight. I'll kick things off — we keep observing an upward trend in the share of our business aimed at clinical. Looking at sequencing consumable revenue overall, you've watched it climb steadily from the late 40s into the mid-40s at this point, and that growth is ongoing. Considering how last year unfolded, clinical segments again outpaced the research segment in growth. So those trajectories are consistently moving in a single direction. As a matter of fact, oncology testing became the biggest single segment we target last year — that's within clinical. It will probably remain our biggest segment for quite a while. It has now surpassed genetic disease research, which, as you're aware, held the top spot for a very long time; we therefore can't give you a precise timeline for when it passes 50%, though the direction is unmistakably toward that.
Sam Samad
executiveYes, John, there's another dynamic I'd add <<inaudible>> of total Illumina revenues. But if you look back over the last — I mean, going to Francis' comments — over the last three years, clinical has grown faster than research. And that simply reflects — both markets are growing very robustly — but it simply reflects the fact that clinical markets when it comes to oncology testing, genetic disease testing, and NIPT have been growing at a really, really impressive clip.
John Sourbeer
analystGreat. Thanks for taking the questions.
Sam Samad
executiveYou’re welcome.
Salli Schwartz
executiveThanks. Just a reminder that you can find a replay of today's call in the Investors section of our site. We appreciate you being with us today. That wraps up our call, and we look forward to our next update after the first fiscal quarter of 2022 comes to a close.
Operator
operatorThat wraps up the Illumina Q4 2021 earnings call. Thanks to everyone for joining us. You can go ahead and disconnect your lines now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Illumina, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Illumina, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Illumina, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.